paclitaxel has been researched along with Cancer of the Ureter in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.56) | 18.2507 |
2000's | 6 (33.33) | 29.6817 |
2010's | 10 (55.56) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Khan, SA; Parajuli, SB; Rayamajhi, A; Sah, S; Sapkota, S | 1 |
Bellmunt, J; Galsky, MD; Sonpavde, G | 1 |
Canil, CM; Eisen, A; Elser, C; Ko, YJ; Mukherjee, SD; Reaume, MN; Sridhar, SS; Winquist, E; Zhang, L | 1 |
Payton, S | 1 |
Bellmunt, J; Chang, SL; Choueiri, TK; Fay, AP; Leow, JJ; Martin-Doyle, W | 1 |
Kamata, S; Yoshinaga, A | 1 |
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
Msaouel, P; Tu, SM; Zhang, M | 1 |
Aziz, A; Dobruch, J; Gontero, P; Hendricksen, K; Kassouf, W; Kluth, LA; Necchi, A; Noon, A; Rink, M; Roghmann, F; Seiler, R; Shariat, SF; Xylinas, E | 1 |
Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J | 1 |
Fukuta, F; Kitamura, H; Kunishima, Y; Masumori, N; Mutoh, M; Shigyo, M; Taguchi, K; Takahashi, A; Tanaka, T; Tsukamoto, T; Yanase, M | 1 |
Cho, IC; Chung, J; Joung, JY; Kim, EK; Kwon, WA; Lee, KH; Park, S; Park, WS; Seo, HK; Yoon, H | 1 |
Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
Matsumura, K; Naganuma, T; Nakatani, T; Sugimura, K; Uchida, J | 1 |
Anagnostopoulos, A; Bamias, A; Constantinides, C; Deliveliotis, Ch; Dimopoulos, MA; Fountzilas, G; Gika, D; Kastritis, E; Kosmidis, P; Zorzou, MP | 1 |
Gallagher, CJ; Johnson, PW; Oliver, RT; Papamichael, D; Waxman, J | 1 |
Burch, PA; Camoriano, JK; Cha, SS; Kaur, JS; Pitot, HC; Richardson, RL; Sargent, DJ | 1 |
Broome, CM; Gutheil, JC; Hussain, M; Markowitz, AB; Vaughn, DJ | 1 |
3 review(s) available for paclitaxel and Cancer of the Ureter
Article | Year |
---|---|
A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Humans; Kidney Neoplasms; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Ureteral Neoplasms; Urothelium | 2014 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Humans; Kidney Neoplasms; Kidney Pelvis; Neoadjuvant Therapy; Nephrectomy; Paclitaxel; Ureter; Ureteral Neoplasms; Urologic Surgical Procedures | 2017 |
6 trial(s) available for paclitaxel and Cancer of the Ureter
Article | Year |
---|---|
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Canada; Carcinoma; Chemistry, Pharmaceutical; Disease-Free Survival; Drug Administration Schedule; Drug Carriers; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Proportional Hazards Models; Time Factors; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Ifosfamide; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2011 |
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; Greece; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Ureteral Neoplasms | 2004 |
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1997 |
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2000 |
Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
9 other study(ies) available for paclitaxel and Cancer of the Ureter
Article | Year |
---|---|
Promising Response of Paclitaxel in Metastatic Transitional Cell Carcinoma of Distal Ureter Complicated with Hydroureteronephrosis: A Case Report.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Hydronephrosis; Lung Neoplasms; Paclitaxel; Renal Insufficiency; Ureter; Ureteral Neoplasms | 2023 |
A new approach to second-line therapy for urothelial cancer?
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
Bladder cancer: second-line nab-paclitaxel for advanced urothelial carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Drug Carriers; Female; Humans; Kidney Neoplasms; Male; Nanoparticles; Paclitaxel; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium | 2013 |
[Long survival in a patient with advanced ureteral carcinoma treated with TIN regimen (paclitaxel, ifosfamide, nedaplatin) and radiotherapy : a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Humans; Ifosfamide; Male; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Time Factors; Tomography, X-Ray Computed; Ureteral Neoplasms | 2014 |
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms | 2017 |
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2009 |
Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Gentamicins; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Paclitaxel; Retrospective Studies; Treatment Failure; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2011 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome; Ureteral Neoplasms; Vinblastine | 2003 |